Patent Review of Novel Biologics Targeting Opioid Use Disorder (2018–2024) DOI
Samuel Obeng, Lance Richard McMahon, Edward Ofori

et al.

ACS Chemical Neuroscience, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 28, 2024

Drug overdose deaths in 2023 the United States exceeded 107,000, with 80,000 of these attributed to opioids alone. The emergence synthetic such as fentanyl and its analogues have worsened opioid epidemic. A novel approach treat use disorder (OUD) has been introduction biologics, which include monoclonal antibodies that bind circulating opioids, preventing them from reaching central nervous system, or peptides antinociceptive effects but lack abuse liability opioids. challenge treatment renarcotization, where an patient revived naloxone can re-enter state residual body. Biologics vaccines are excellent strategies demonstrated prevent renarcotization. In this review, we retrieved discussed patents filed past six (6) years focus on biologics reported treatments for OUD. We also provide a perspective therapeutics OUD overdose.

Language: Английский

Protein-Based Degraders: From Chemical Biology Tools to Neo-Therapeutics DOI

Lisha Ou,

Mekedlawit Setegne,

Jeandele Elliot

et al.

Chemical Reviews, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 17, 2025

The nascent field of targeted protein degradation (TPD) could revolutionize biomedicine due to the ability degrader molecules selectively modulate disease-relevant proteins. A key limitation broad application TPD is its dependence on small-molecule ligands target proteins interest. This leaves unstructured or those lacking defined cavities for binding out scope many technologies. use proteins, peptides, and nucleic acids (otherwise known as "biologics") protein-targeting moieties in degraders addresses this limitation. In following sections, we provide a comprehensive critical review studies that have used peptides mediate hence functional control otherwise challenging targets. We describe existing platforms protein/peptide-based ligand identification drug delivery systems might be exploited biologic-based degraders. Throughout Review, underscore successes, challenges, opportunities using protein-based chemical biology tools spur discoveries, elucidate mechanisms, act new therapeutic modality.

Language: Английский

Citations

0
The higher benefit of lecanemab in males compared to females in CLARITY AD is probably due to a real sex effect DOI Creative Commons
Daniel Andrews, Simon Ducharme, Howard Chertkow

et al.

Alzheimer s & Dementia, Journal Year: 2025, Volume and Issue: 21(1)

Published: Jan. 1, 2025

Abstract INTRODUCTION The phase 3 trial CLARITY AD found lecanemab slowed cognitive decline by 27%. However, subgroup analyses indicated a significant 31% sex difference in the effect and suggested no or limited effectiveness females. We used simulations constrained design to determine whether that reflects pre‐existing Alzheimer's disease progression was random event. METHODS Simulations were generated using linear mixed models of fit data from Disease Neuroimaging Initiative participants satisfying inclusion criteria. RESULTS statistically non‐significant 7.9% smaller rate our cohort's males versus females does not explain AD's lecanemab's effect. A ≥ occurred randomly only 12 10,000 (0.0012 probability). DISCUSSION probably random. Lecanemab is likely less effective than males, but we cannot conclude drug ineffective Highlights more clinically Forest plots should report subgroup‐specific effects well‐powered subgroups. Trial based on real enable investigation effects. efficacy could be linked its action mechanism.

Language: Английский

Citations

0
Construction and application of a large capacity VNAR library from the whitespotted bamboo shark (Chiloscyllium playgiosum) DOI Creative Commons
Hao Li, Litong Liu,

Xinyi Kang

et al.

Acta Pharmaceutica Sinica B, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

Citations

0
Hierarchical clustering of therapeutic proteins based on agitation-induced aggregation propensity and its relation to physicochemical parameters DOI

Rio Okada,

K Shibata,

Risa Shibuya

et al.

European Journal of Pharmaceutical Sciences, Journal Year: 2025, Volume and Issue: 208, P. 107060 - 107060

Published: March 13, 2025

Language: Английский

Citations

0
A Review on the Stability Challenges of Advanced Biologic Therapeutics DOI Creative Commons
Sruthi Sarvepalli,

Shashank Reddy Pasika,

Vinod Verma

et al.

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(5), P. 550 - 550

Published: April 23, 2025

Advanced biotherapeutic systems such as gene therapy, mRNA lipid nanoparticles, antibody–drug conjugates, fusion proteins, and cell therapy have proven to be promising platforms for delivering targeted biologic therapeutics. Preserving the intrinsic stability of these advanced therapeutics is essential maintain their innate structure, functionality, shelf life. Nevertheless, various challenges obstacles arise during formulation development throughout storage period due complex nature sensitivity stress factors. Key concerns include physical degradation chemical instability factors fluctuations in pH temperature, which results conformational colloidal instabilities biologics, adversely affecting quality therapeutic efficacy. This review emphasizes key issues associated with approaches identify overcome them. In brittleness viral vectors encapsulation limits stability, requiring use stabilizers, excipients, lyophilization. Keeping cells viable whole process, from culture final formulation, still a major difficulty. therapeutics, stabilization strategies optimization nucleotides compositions are used address both nanoparticles. Monoclonal antibodies colloidally conformationally unstable. Hence, buffers stabilizers useful stability. Although proteins monoclonal share structural similarities, they show similar pattern instability. Antibody–drug conjugates possess conjugation linker outlines biotherapeutics provides insights into challenges.

Language: Английский

Citations

0
Advanced applications of Nanodiscs-based platforms for antibodies discovery DOI

Kristina O Baskakova,

Pavel Kuzmichev, Mikhail S. Karbyshev

et al.

Biophysical Chemistry, Journal Year: 2024, Volume and Issue: 313, P. 107290 - 107290

Published: Oct. 1, 2024

Language: Английский

Citations

3
Implemention of Innovative Process Analytical Technologies to Characterize Critical Quality Attributes of Co‐Formulated Monoclonal Antibody Products DOI

Apurva Godbole,

Lei Chen, Jay Desai

et al.

Biotechnology and Bioengineering, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 7, 2024

Characterizing co-formulated monoclonal antibodies (mAbs) poses significant challenges in the pharmaceutical industry. Due to high structural similarity of mAbs, traditional analytical methods, compounded by lengthy method development process, hinder product and manufacturing efficiency. There is increasing critical need industry streamline approaches, minimizing time resources, ensuring a rapid clinical entry cost-effective manufacturing. This study investigates application process technologies (PAT) address such challenges. Our investigation introduces two complementary technologies, on-line ultra-performance liquid chromatography (online UPLC) multimode fluorescence spectroscopy (MMFS), as potential PAT tools tailored for characterizing quality attributes (CQA) mAb products. Specifically, CQAs under evaluation include total protein concentration mAbs within co-formulation ratio A B. Online UPLC enables direct automated measurement through physical separation, while MMFS determines them non-destructive more swift manner based on chemometric modeling. We demonstrate these technologies' comparable performance conventional alongside substantial benefits reduced turnaround decreased laboratory efforts. Ultimately, integrating innovative expedites delivery therapeutic solutions patients enhances efficiency, aligning with imperative translation scientific discoveries into benefits.

Language: Английский

Citations

0
A closer look at pathogenic amyloid-β in Alzheimer’s disease using cryo-electron microscopy: a narrative review DOI
Yang Gao, Sophia Schedin‐Weiss, Lars O. Tjernberg

et al.

Advanced technology in neuroscience ., Journal Year: 2024, Volume and Issue: 1(2), P. 177 - 187

Published: Nov. 27, 2024

Alzheimer’s disease is a progressive neurodegenerative disorder that affects millions of people worldwide. The identification amyloid-β in brains, together with the association mutations precursor protein pathology, basis amyloid cascade hypothesis, which suggests plays central role pathogenesis. Recent studies have further highlighted intraneuronal development. Moreover, success anti-amyloid-β immunotherapies supports emphasizing importance targeting specific conformations to achieve better therapeutic outcomes. In recent years, cryo-electron microscopy has become an invaluable tool for obtaining near-atomic resolution images assemblies, and multiple structures brain-derived fibrils been elucidated. this article, we review pathogenic according hypothesis explore relationship between accumulation development key pathological features disease—amyloid plaques neurofibrillary tangles. We also connect aggregates amyloid-β-targeting treatment highlight advances future research directions. application can provide molecular insights into structure, expected help uncover underlying mechanisms new strategies clearance aggregates.

Language: Английский

Citations

0
Patent Review of Novel Biologics Targeting Opioid Use Disorder (2018–2024) DOI
Samuel Obeng, Lance Richard McMahon, Edward Ofori

et al.

ACS Chemical Neuroscience, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 28, 2024

Drug overdose deaths in 2023 the United States exceeded 107,000, with 80,000 of these attributed to opioids alone. The emergence synthetic such as fentanyl and its analogues have worsened opioid epidemic. A novel approach treat use disorder (OUD) has been introduction biologics, which include monoclonal antibodies that bind circulating opioids, preventing them from reaching central nervous system, or peptides antinociceptive effects but lack abuse liability opioids. challenge treatment renarcotization, where an patient revived naloxone can re-enter state residual body. Biologics vaccines are excellent strategies demonstrated prevent renarcotization. In this review, we retrieved discussed patents filed past six (6) years focus on biologics reported treatments for OUD. We also provide a perspective therapeutics OUD overdose.

Language: Английский

Citations

0